AIM Immunotech Inc. - Form 8-K Summary
Business Context and Reporting Period
This is a Current Report (Form 8-K) filed by AIM Immunotech Inc. on October 29, 2025. The company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol "AIM". The report addresses corporate governance updates rather than operational or financial performance.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a legal filing regarding corporate charter amendments and does not contain financial statements or operational data.
Material Changes
The primary material event reported is the entry into a Material Definitive Agreement (Item 1.01). Specifically, the company has amended and restated its Certificate of Incorporation. This new document supersedes all previous individual exhibits containing pieces of the charter.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly procedural, focusing on the execution of the amended Certificate of Incorporation.
Key Facts for Investor Verification
- Event Date: October 29, 2025.
- Key Action: Filing of an amended and restated Certificate of Incorporation (Exhibit 3.1(i)).
- Signatory: Thomas K. Equels, CEO.
- Financial Data: None provided in this specific filing; investors should refer to the most recent 10-K or 10-Q for financial metrics.